The proposed acquisition consideration represents an equity value for Myovant of $2.4 billion and an enterprise value of $2.5 billion.
To set up 50 lifestyle modification centres across the UAE in the next 24 months
NULIBRY is a first-in-class cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A.
Evusheld significantly reduced risk of severe COVID-19 or death in TACKLE Phase III treatment trial
Expanding precision medicine, ARTIS icono is designed to enable a wide procedure mix in a single interventional suite
These moves are designed to strengthen the company’s medical and scientific focus and support its continued record growth through closer alignment of all aspects of strategy, sales, and delivery to delight customers
He takes over leadership of Cell & Gene from Jean-Christophe Hyvert, enabling Jean-Christophe to increase his focus on his role as President of the Biologics Division
Pfizer’s Paxlovid is approved by US FDA for COVID treatment
Investment further strengthens Merck's "Big 3," the key drivers for increasing Group sales to approximately € 25 billion by 2025
Subscribe To Our Newsletter & Stay Updated
